10x Genomics Stock Performance
| TXG Stock | USD 14.11 0.38 2.77% |
On a scale of 0 to 100, 10X Genomics holds a performance score of 17. The firm shows a Beta (market volatility) of 2.21, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, 10X Genomics will likely underperform. Please check 10X Genomics' expected short fall, as well as the relationship between the rate of daily change and relative strength index , to make a quick decision on whether 10X Genomics' price patterns will revert.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in 10X Genomics are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. Despite nearly uncertain basic indicators, 10X Genomics reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 1 | Five Day Return 10.06 | Year To Date Return (2.27) | Ten Year Return (73.71) | All Time Return (73.71) |
Last Split Factor 1:2 | Last Split Date 2006-07-17 |
1 | 10x Genomics Inc Q1 2025 Earnings Call Highlights Navigating Challenges with Strategic ... | 05/09/2025 |
2 | 10x Genomics Announces Patent Litigation Settlement Agreement with Bruker TXG Stock News | 05/14/2025 |
3 | Disposition of 4044 shares by Adam Taich of 10X Genomics at 8.2993 subject to Rule 16b-3 | 05/22/2025 |
4 | Acquisition by Kosaraju Sridhar of 15357 shares of 10X Genomics subject to Rule 16b-3 | 06/03/2025 |
5 | Disposition of 1000 shares by Serge Saxonov of 10X Genomics subject to Rule 16b-3 | 06/09/2025 |
6 | 10x Genomics Settles Patent Dispute With Bruker | 06/23/2025 |
7 | 10x Genomics Price Target Raised by Barclays Analyst TXG Stock News | 06/24/2025 |
8 | 10x Genomics Inc Shares Up 4.23 percent on Jul 2 | 07/02/2025 |
9 | 10x Genomics Inc Shares Down 7.49 percent on Jul 7 | 07/07/2025 |
10 | Acadia Healthcare, 10x Genomics, Amphastar Pharmaceuticals, Myriad Genetics, and QuidelOrtho Stocks Trade Down, What You Need To Know - TradingView | 07/11/2025 |
11 | 10x Genomics Inc and ASTAR GIS Collaborate on TISHUMAP Study TXG stock news | 07/17/2025 |
12 | 10x Genomics Inc Shares Down 4.65 percent on Jul 21 | 07/21/2025 |
13 | 10x Genomics Receives Consensus Recommendation of Hold from Brokerages | 07/24/2025 |
| Begin Period Cash Flow | 359.3 M | |
| Total Cashflows From Investing Activities | -32.6 M |
10X Genomics Relative Risk vs. Return Landscape
If you would invest 848.00 in 10X Genomics on April 26, 2025 and sell it today you would earn a total of 563.00 from holding 10X Genomics or generate 66.39% return on investment over 90 days. 10X Genomics is generating 0.9033% of daily returns assuming volatility of 4.0166% on return distribution over 90 days investment horizon. In other words, 35% of stocks are less volatile than 10X, and above 82% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
10X Genomics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for 10X Genomics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as 10X Genomics, and traders can use it to determine the average amount a 10X Genomics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2249
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | TXG | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.02 actual daily | 36 64% of assets are more volatile |
Expected Return
| 0.9 actual daily | 18 82% of assets have higher returns |
Risk-Adjusted Return
| 0.22 actual daily | 17 83% of assets perform better |
Based on monthly moving average 10X Genomics is performing at about 17% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of 10X Genomics by adding it to a well-diversified portfolio.
10X Genomics Fundamentals Growth
10X Stock prices reflect investors' perceptions of the future prospects and financial health of 10X Genomics, and 10X Genomics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on 10X Stock performance.
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.25) % | ||||
| Operating Margin | (0.31) % | ||||
| Current Valuation | 1.34 B | ||||
| Shares Outstanding | 111.09 M | ||||
| Price To Book | 2.39 X | ||||
| Price To Sales | 2.71 X | ||||
| Revenue | 610.78 M | ||||
| Gross Profit | 427.01 M | ||||
| EBITDA | (133.99 M) | ||||
| Net Income | (182.63 M) | ||||
| Cash And Equivalents | 499.73 M | ||||
| Cash Per Share | 4.39 X | ||||
| Total Debt | 82.61 M | ||||
| Debt To Equity | 0.13 % | ||||
| Current Ratio | 5.65 X | ||||
| Book Value Per Share | 5.74 X | ||||
| Cash Flow From Operations | 6.66 M | ||||
| Earnings Per Share | (1.30) X | ||||
| Market Capitalization | 1.69 B | ||||
| Total Asset | 918.64 M | ||||
| Retained Earnings | (1.47 B) | ||||
| Working Capital | 466.75 M | ||||
About 10X Genomics Performance
By analyzing 10X Genomics' fundamental ratios, stakeholders can gain valuable insights into 10X Genomics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if 10X Genomics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if 10X Genomics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 154.53 | 138.06 | |
| Return On Tangible Assets | (0.20) | (0.21) | |
| Return On Capital Employed | (0.24) | (0.26) | |
| Return On Assets | (0.20) | (0.21) | |
| Return On Equity | (0.26) | (0.27) |
Things to note about 10X Genomics performance evaluation
Checking the ongoing alerts about 10X Genomics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for 10X Genomics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| 10X Genomics appears to be risky and price may revert if volatility continues | |
| The company reported the last year's revenue of 610.78 M. Reported Net Loss for the year was (182.63 M) with profit before taxes, overhead, and interest of 427.01 M. | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: 10x Genomics Receives Consensus Recommendation of Hold from Brokerages |
- Analyzing 10X Genomics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether 10X Genomics' stock is overvalued or undervalued compared to its peers.
- Examining 10X Genomics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating 10X Genomics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of 10X Genomics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of 10X Genomics' stock. These opinions can provide insight into 10X Genomics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for 10X Stock analysis
When running 10X Genomics' price analysis, check to measure 10X Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 10X Genomics is operating at the current time. Most of 10X Genomics' value examination focuses on studying past and present price action to predict the probability of 10X Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 10X Genomics' price. Additionally, you may evaluate how the addition of 10X Genomics to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |